il17

GSK2981278 (ROR gama modulator 1) 是 RORγ的选择性反向激动剂。它能够抑制 il17启动子的激活，并且干扰 RORγ-DNA 结合。

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

IL-17 modulator 4 是 IL-17 modulator 1 的前药，IL-17 modulator 1 可以作为 IL-17 的有效调节剂。

IL-17 modulator 1 is an orally active small molecule. It is highly efficacious in modulating IL-17 and can effectively prevent, treat, or ameliorate various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis.

IL-17 modulator 4 sulfate is a prodrug of IL-17 modulator 1 . IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.

IL-17 modulator 3 (US20200247785A1) is a chemical compound that acts as an IL-17 modulator. It has potential applications in researching inflammation, cancer, and autoimmune diseases.

Dersalazine (Dersalazine Free Base) 是血小板活化因子抑制剂，通过下调 IL-17表达，在不同啮齿动物型结肠炎中发挥肠道抗炎活性，对溃疡性结肠炎患者具有潜在疗效。

IL-17A inhibitor 1 是 IL-17A 的抑制剂，在alphalisa assay 中的IC50为 <9.45 nM。IL-17A inhibitor 1抑制HT-29 细胞的 IC50 值为 9.3 nM。

AX-024 hydrochloride (AX-024 HCl) 是一种细胞因子释放抑制剂，可强烈抑制 IL-6、TNFα、IFN-γ、IL-10 和 IL-17A 的产生。它是口服可利用的 TCR-Nck 相互作用抑制剂，可选择性地抑制 TCR 触发的 T 细胞活化。它通过靶向 SH3结构域调节细胞信号传导，具有低毒、高效和高选择性的特点。

IL-17A antagonist 1 是一种 IL-17A 拮抗剂，可用于研究和白介素相关的炎症和免疫疾病。

IL-17A antagonist 3 is an IL-17A antagonist.

TMP778 is an effective and selective RORγt inverse agonist (IC50: 7 nM in FRET assay).

Y-320 是一种免疫调节剂，能阻碍IL-15刺激CD4 T 细胞后的IL-17的产生，IC50=20~60 nM。

IL-17-IN-1 (26) 为一种口服活性的IL-17抑制剂，其对IL-17A及IL-6的释放展现出卓越的抑制效果，IC50分别为0.013 μM与0.004 μM。在大鼠关节炎模型中，IL-17-IN-1 (26) 显著减轻了膝关节的肿胀状况。

IL-17-IN-3 (compound 11) 是一种IL-17A的抑制剂，其IC50值为35 nM。在一项针对大鼠的耐受性研究中，以高达300 mg kg 天的剂量连续四天给药后，没有观察到IL-17-IN-3引起任何不良反应。

Ixekizumab (LY2439821) 是一种人源化 IgG4 单克隆抗体，可选择性结合和中和白细胞介素 IL-17A ，Kd 值<3 pM。Ixekizumab 科阻断 IL-17A 与 IL-17RA 的结合，但不与其他 IL-17 家族成员结合。Ixekizumab 用于治疗中重度斑块型银屑病、银屑病关节炎和牛皮癣。

IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis.

BMS-986251 is a potent and specific RORγt inverse agonist that exerts its action via oral administration. It shows an EC 50 of 12 nM for RORγt GAL4. In human whole blood assay, BMS-986251 effectively inhibits IL-17 with an EC 50 of 24 nM. Furthermore, BMS-986251 exhibits strong therapeutic effects in mouse acanthosis and Imiquimod-induced models, which are commonly used preclinical models for psoriasis.

IL-17A modulator-1 is an effective inhibitor of IL-17A activity, exhibiting a pIC 50 value of 8.2. This compound holds great promise for studying diseases and disorders that involve the modulation of IL-17A, such as immune-related diseases, autoimmune pathologies, cancer, and neurodegenerative disorders.

IL-17A modulator-2, exhibits inhibitory properties towards IL-17A, with a pIC50 of 8.3. Its effectiveness lies in attenuating the biological effects associated with IL-17A activity. IL-17A modulator-2 finds utility in the study of diseases and disorders characterized by dysregulated IL-17A modulation, such as those involving immune dysfunction, autoimmune pathology, cancer, and neurodegenerative conditions.

(R)-IL-17 modulator 4 是 IL-17 modulator 4 的 R 构型形式，是 IL-17 modulator 1 的前药。其中 IL-IL-17 modulator 1 是一种高效的、口服具有活力的 IL-17 调节剂。

IL-17Amodulator-3 是IL-17A 的调节剂。IL-17Amodulator-3 抑制 IL-17A A，IC50值 ＜10 μM。IL-17Amodulator-3 可以用于炎症、癌症和自身免疫疾病的研究。

IL-17 modulator5 是IL-17的抑制剂，其IC50值为 1 nM。

Risankizumab (BI 655066) 是一种人源化靶向 IL-23 p19 亚基的 IgG 单克隆抗体(Kd <10 pM)。 Risankizumab 能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生，IC50 值为 2 pM。Risankizumab 可用于预防和治疗如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病类的免疫性和炎症性疾病。